CompletedNot Applicable

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

Japan61 participantsStarted 2023-03-07

Plain-language summary

To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual post-marketing use.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The patients who started treatment with LYNPARZA for the first time for the approved indication "Adjuvant treatment for patients with BRCA-mutated HER2 negative high recurrent risk breast cancer" Exclusion Criteria: * Patients who have no treatment history with LYNPARZA

What they're measuring

Incidence of bone marrow suppression

Timeframe: from baseline to 1year

Trial details

NCT IDNCT05677308

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-02-18

View on ClinicalTrials.gov More Breast Cancer trials